Tyra’s dabogratinib advances to phase III for MIBC
Dabogratinib, an oral FGFR3 inhibitor, reported phase II efficacy and safety in intermediate-risk MIBC, with 79% response and 64% CR rates at 60 mg. Phase III trials and UTUC expansion are planned.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.